Tonix Pharmaceuticals (TNXP) stock gains as the company posts peer-reviewed data for pain drug TNX-102 and new data for mpox ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its ...

Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh pharma ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

Read about Tonix Pharmaceuticals Holding Corp (TNXP:XNAS) stock and today's latest news and financial updates.

Tonix Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

Initiate Hold rating on Tonix Pharmaceuticals due to increased approval odds for TNX-102 SL but concerns over commercial prospects and potential shareholder dilution. TNX-102 SL shows strong Phase ...

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered ...

Tonix Pharmaceuticals' new drug shows promise in relieving fibromyalgia pain without addiction risk, according to Phase 3 trial results.

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...